Immediate Impact
1 by Nobel laureates 76 standout
Citing Papers
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2024 Standout
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
2024 Standout
Works of Julia Kazakin being referenced
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
2018
Abstract B151: In FGFR2 driven tumors, preclinical pharmacokinetics (PK), pharmacodynamics (PD) and efficacy translate into clinical activity of ARQ 087
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Julia Kazakin | 231 | 373 | 108 | 254 | 22 | 546 | |
| Terence Hall | 270 | 301 | 99 | 222 | 16 | 508 | |
| Maria D. Begnami | 175 | 152 | 213 | 274 | 21 | 543 | |
| Yunxian Mo | 131 | 156 | 156 | 192 | 32 | 527 | |
| Koro Sakoda | 221 | 387 | 115 | 325 | 19 | 601 | |
| Aikseng Ooi | 325 | 158 | 207 | 272 | 18 | 647 | |
| J C Givel | 121 | 129 | 94 | 271 | 19 | 557 | |
| Hirotoshi Yonemasu | 178 | 260 | 162 | 235 | 36 | 584 | |
| Tommaso Stecca | 141 | 299 | 79 | 262 | 16 | 514 | |
| Vincenzo Rosario Iaffaioli | 133 | 105 | 76 | 310 | 25 | 511 | |
| Ioannis Xanthakis | 123 | 125 | 156 | 340 | 30 | 506 |
All Works
Loading papers...